Healthcare Industry News: olanzapine
News Release - December 26, 2006
U.S. Appeals Court Upholds Lilly's 2011 Zyprexa Patent
INDIANAPOLIS, Dec. 26 (HSMN NewsFeed) -- The Court of Appeals for the Federal Circuit in Washington, D.C., today affirmed the U.S. District Court's decision that upheld Eli Lilly and Company's (NYSE: LLY ) Zyprexa® patent expiring in 2011. Oral arguments were heard on April 6, 2006, by the appeals court. On April 14, 2005, in the case of Eli Lilly and Company v. Zenith Goldline Pharmaceuticals et al., the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly on all of the generic companies' patent challenges, including obviousness, double patenting, inequitable conduct, anticipation, and public use."Today's appeals court ruling not only affirms the validity of our patent, but upholds patent law that helps enable the significant investments required to develop the next generation of revolutionary medicines for the patients who need them," said Sidney Taurel, Lilly chairman and chief executive officer.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY
Zyprexa®(olanzapine, Lilly)
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Most Patients on Lilly's Omvoh(R) (mirikizumab-mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two YearsMediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
